Clinical Trials Using Docetaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Docetaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 108

  • Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

    GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab, chemotherapy or other immune therapies. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or dostarlimab or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
    Location: 6 locations

  • Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients with Stage III-IV or Recurrent Endometrioid Endometrial Cancer

    This phase II trial studies how well enzalutamide, carboplatin, and paclitaxel work in treating patients with endometrioid endometrial cancer that is stage III-IV or has come back (recurrent). Androgens can cause the growth of endometrioid endometrial cancer. Antihormone therapy, such as enzalutamide may lessen the amount of androgen made by the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving enzalutamide, carboplatin, and paclitaxel may work better in treating patients with endometrioid endometrial cancer.
    Location: 6 locations

  • Docetaxel with or without Ascorbic Acid in Treating Patients with Metastatic Prostate Cancer

    This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid (vitamin C) is a water-soluble vitamin that may help inhibit the growth of cancer cells. It is not yet known whether docetaxel works better when given with or without ascorbic acid in treating prostate cancer.
    Location: 7 locations

  • Nivolumab, Docetaxel, and Androgen Deprivation Therapy for the Treatment of Metastatic, Hormone-Sensitive Prostate Cancer with DNA Damage Repair Defects or Inflamed Tumors

    This phase II trial studies how well nivolumab, docetaxel, androgen deprivation therapy (ADT) work in treating patients with hormone-sensitive prostate cancer with deoxyribonucleic acid (DNA) damage repair defects or inflamed tumors that has spread to other places in the body (metastatic). Testosterone can cause the growth of prostate cancer cells. ADT, or hormonal therapy, may help fight prostate cancer by cutting off the supply of testosterone. Nivolumab is an antibody (a type of human protein) that works by stimulating the body’s immune system to recognize and fight cancer cells. Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormonal therapy and chemotherapy may make cancer cells more recognizable to the immune system, and make cancer cells more susceptible to nivolumab immunotherapy. The purpose of this study is to examine the activity and safety of hormonal therapy combined with docetaxel chemotherapy and nivolumab immunotherapy for patients with prostate cancer.
    Location: 5 locations

  • ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head / Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

    A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
    Location: 7 locations

  • Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001 / KEYLYNK-001 / ENGOT-ov43 / GOG-3036)

    The purpose of this study is to assess the efficacy and safety of treatment with carboplatin / paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses are that the combination of pembrolizumab plus carboplatin / paclitaxel* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin / paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and / or Overall Survival (OS), and that the combination of pembrolizumab plus carboplatin / paclitaxel followed by continued pembrolizumab is superior to carboplatin / paclitaxel alone with respect to PFS per RECIST 1.1 and / or OS.
    Location: 5 locations

  • Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585 / KEYNOTE-585)

    The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. The primary study hypotheses are that: - Neoadjuvant and adjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab is superior to neoadjuvant and adjuvant placebo plus chemotherapy, followed by adjuvant placebo in terms of Overall Survival (OS), and Event-free Survival (EFS) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), and - Neoadjuvant pembrolizumab plus chemotherapy is superior to neoadjuvant placebo plus chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.
    Location: 6 locations

  • Chemotherapy and Pembrolizumab in Treating Patients with Stage IV Non-small Lung Cancer Previously Treated with PD-1 or PD-L1 Inhibitor

    This phase II trial studies how well chemotherapy and pembrolizumab work in treating patients with stage IV non-small lung cancer previously treated with PD-1 or PD-L1 Inhibitor. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, or pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy and pembrolizumab may work better in controlling cancer and treating patients with non-small cell lung cancer.
    Location: 5 locations

  • Docetaxel and Capecitabine in Treating Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    This phase II trial studies the side effects and how well docetaxel and capecitabine work in treating patients with squamous cell (thin, flat cells) carcinoma of the head and neck that has come back or spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 5 locations

  • TTX-030 in Combination With Immunotherapy and / or Chemotherapy in Subjects With Advanced Cancers

    This is a phase 1 / 1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and / or standard chemotherapies.
    Location: 6 locations

  • A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

    The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
    Location: 8 locations

  • Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080 / MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008 / E7080-G000-316 / LEAP-008)

    This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080 / MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1 / PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR).
    Location: 4 locations

  • Chemotherapy, Nivolumab, and Intensity-Modulated Radiation Therapy in Treating Patients with Stage III-IV Laryngeal or Hypopharyngeal Cancer

    This phase II trial studies how well chemotherapy, nivolumab, and intensity-modulated radiation therapy work in treating patients with stage III-IV laryngeal or hypopharyngeal cancer. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Giving chemotherapy with nivolumab and intensity-modulated radiation therapy may work better in treating patients with laryngeal and hypopharyngeal cancer than standard of care chemotherapy and radiation therapy.
    Location: 4 locations

  • A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

    This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
    Location: 4 locations

  • GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

    The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed / refractory (R / R) Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation (Part 2). Part 1 (dose escalation) will enroll subjects with advanced, selected solid tumors. Subjects will receive escalating doses of GSK3359609 and tremelimumab in combination in Part 1. Part 2 is randomized expansion and will enroll subjects with R / R HNSCC who have disease progression after receiving at least 1 platinum-based chemotherapy and at least 1 anti-programmed death receptor protein-1 (PD-1) / anti-programmed death-ligand 1 (PD-L1) therapy, whether in combination or separately. In Part 2, subjects will be randomized in a ratio of 2:1 to receive either GSK3359609 in combination with tremelimumab at the recommended Phase 2 dose or investigators choice of a single-agent standard of care (SOC) therapy including paclitaxel, docetaxel or cetuximab. The total duration of subjects in the study will be approximately 4 years.
    Location: 4 locations

  • ADI-PEG 20, Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Unresectable or Metastatic Soft Tissue Sarcoma, Osteosarcoma, Ewing’s sarcoma, or Small Cell Lung Cancer

    This phase II trial studies how well pegargiminase (ADI-PEG 20) works in combination with gemcitabine hydrochloride and docetaxel in treating patients with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer that cannot be removed surgically (unresectable) or that has spread to other parts of the body (metastatic). ADI-PEG 20 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ADI-PEG 20 with gemcitabine hydrochloride and docetaxel may work better in treating patients with soft tissue sarcoma.
    Location: 4 locations

  • Androgen-Deprivation Therapy, Apalutamide, and Radiation Therapy Followed by Docetaxel in Treating Patients with Recurrent Prostate Cancer after Radical Prostatectomy

    This phase II trial studies how well androgen-deprivation therapy, apalutamide, and radiation therapy followed by docetaxel work in treating patients with prostate cancer that has come back (recurrent) after radical prostatectomy. Hormone therapy such as androgen-deprivation therapy may fight prostate cancer by blocking the production and interfere with the action of hormones. Apalutamide may help stop or slow the growth of prostate cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving androgen-deprivation therapy, apalutamide, radiation therapy followed by docetaxel may work better in treating patients with prostate cancer.
    Location: 4 locations

  • Selinexor and Docetaxel in Treating Participants with Stage IV KRAS Mutant Non-Small Cell Lung Cancer

    This phase I / II trial studies the safety and best dose of selinexor and docetaxel in treating participants with stage IV KRAS-mutation non-small cell lung cancer that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor and docetaxel may work better in treating participant with stage IV KRAS mutant non-small cell lung cancer.
    Location: 4 locations

  • Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

    To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: - To compare the neutropenia (incidence of Grade 4 neutropenia [absolute neutrophil count (ANC) < 0.5 × 10^9 / L]) on Day 8 (+ / - 1 day) of Cycle 1), DoR, neutrophil count on Day 8 (+ / - 1 day) of Cycle 1, incidence of docetaxel dose reduction and / or docetaxel dose withheld in Cycle 2 due to neutropenia in Cycle 1, QoL (EORTC QLQ-C30 [item 30, average overall quality of life over all observable weeks]), ORR, and PFS in patients with NSCLC treated in the DP Arm to patients treated in the D Arm as 2nd- or 3rd-line therapy for advanced or metastatic disease. - To compare the safety and adverse events profile of the DP Arm to D Arm. - To compare dose intensity of docetaxel (percent dose administered compared to dose assigned) between the 2 treatment arms. - To evaluate population pharmacokinetics in patients enrolled in China and rest of world (RoW).
    Location: 4 locations

  • Docetaxel with or without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

    This phase II trial studies how well docetaxel works with or without bintrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bintrafusp alfa, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel and bintrafusp alfa in combination may work better in treating non small-cell lung cancer compared to docetaxel alone.
    Location: 3 locations

  • Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

    This is a Phase 1b / 2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
    Location: 7 locations

  • Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

    A Phase 3 Study to Compare AMG 510 with Docetaxel in Non-Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
    Location: 7 locations

  • Nivolumab and Standard Chemotherapy before Surgery in Treating Patients with Inflammatory Breast Cancer

    This phase II trial studies how well nivolumab and standard chemotherapy work before surgery in treating patients with inflammatory breast cancer. Immunotherapy with a monoclonal antibody such as nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a protein that is present on different types of cells in the immune system and controls parts of the immune system by shutting it down. Antibodies that block PD-1 can potentially prevent PD-1 from shutting down the immune system, thus allowing immune cells to recognize and destroy tumor cells. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to determine whether the addition of nivolumab to standard chemotherapy improves response rate in patients with inflammatory breast cancer.
    Location: 3 locations

  • Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

    This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma.
    Location: 3 locations

  • A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and / or Refractory Solid Tumors

    An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R / R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R / R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).
    Location: 6 locations